Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Recent developments in radioimmunotherapy

K J Harrington¹, A A Epenetos

¹Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))

|January 1, 1994

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.

Oral oncology·2023

Same author

OX40 and 4-1BB delineate distinct immune profiles in sarcoma.

Oncoimmunology·2022

Same author

Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020

Same author

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Clinical and translational radiation oncology·2018

Same author

An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.

Clinical oncology (Royal College of Radiologists (Great Britain))·2018

Radioimmunotherapy (RIT) shows promise for cancer treatment, with ongoing research focusing on optimizing antibody, chelator, and radioisotope components. Further advancements in targeting and dose delivery are needed for RIT to become a radical therapy option.

Area of Science:

Oncology
Immunology
Radiochemistry

Background:

Monoclonal antibody advancements have revitalized interest in radioimmunotherapy (RIT) for various cancers.
Significant research is dedicated to understanding and improving RIT's efficacy and safety.
Optimizing targeting and minimizing normal tissue toxicity are key research objectives.

Purpose of the Study:

To review the current state of radioimmunotherapy research.
To identify factors influencing RIT efficacy and therapeutic index.
To discuss the potential integration of RIT into radical and multimodality cancer treatment regimens.

Main Methods:

Review of scientific literature and clinical trial data.
Analysis of antibody, chelator, and radioisotope optimization strategies.

Related Experiment Videos

Investigation of host and tumor factors affecting RIT delivery and response.

Main Results:

Phase I and II trials in various tumor types have yielded promising, though not yet curative, results.
Understanding of target cell factors influencing low dose-rate RIT response has improved.
Current research focuses on enhancing tumor cell targeting and increasing radiation dose delivery.

Conclusions:

Radical RIT remains a research goal, requiring improved tumor targeting and higher radiation doses.
RIT is currently best utilized in multimodality protocols for tumor boosts or in adjuvant settings for minimal residual disease.